文献速递甲状腺疾病肥胖与代谢综合征

原发性甲状腺功能减退合并重度肥胖患者减重手术后左甲状腺素替代剂量:德黑兰肥胖治疗研究

Thyroid Hormone Replacement Dosing after Bariatric Surgery in Patients with Primary Hypothyroidism And Severe Obesity: Tehran Obesity Treatment Study.
PubMed 文献 · Thyroid · 2024-09-04

本研究为三年前瞻性队列研究,纳入1030例甲状腺功能减退患者,分别接受袖状胃切除术(SG,n=707,女性88.3%)或单吻合口胃旁路术(OAGB,n=323,女性92%),随访36个月。结果显示两术式多数患者左甲状腺素(LT4)剂量减少或不变,LT4/脂肪质量比值在SG和OAGB组均显著升高,OAGB组变化更大。

要点

  • SG组随访第3年56.1%患者LT4剂量减少,24.4%增加;OAGB组33.3%减少,9.1%增加。
  • SG组TSH随时间下降(ptrend<0.001),OAGB组TSH和T4无显著变化。
  • 两组LT4/脂肪质量比值36个月较基线显著升高,OAGB组变化大于SG组(pbetween=0.060)。

核心结论

  • 多数甲状腺功能减退患者在SG或OAGB术后36个月LT4剂量减少或不变。
  • SG和OAGB术后LT4/脂肪质量比值均显著升高,OAGB组变化更大。
  • 作者提出需在更大样本和更长随访中进一步研究以确认结果。

研究设计与样本

  • 三年前瞻性队列研究,纳入1030例甲状腺功能减退患者,接受SG(n=707,女性88.3%)或OAGB(n=323,女性92%),随访36个月。
  • 采用生物电阻抗分析仪评估体成分,LT4需求通过广义估计方程(GEE)分析,以体重为时变协变量校正。

主要发现

  • 随访期间OAGB组TSH(mIU/L)和T4(ng/dL)无显著变化;SG组TSH随时间下降(ptrend<0.001)。
  • 随访第3年,SG组56.1%和OAGB组33.3%患者LT4(μg/day)剂量减少,SG组24.4%和OAGB组9.1%患者剂量增加。
  • GEE分析显示36个月随访时LT4/脂肪质量(μg/kg)比值较基线显著升高:SG组从1.8(1.5-2.2)升至2.7(2.0-3.5),ptrend=0.039;OAGB组从1.7(1.4-2.2)升至3.2(2.7-4.8),ptrend<0.001。
  • OAGB组LT4/脂肪质量剂量调整大于SG组(pbetween=0.060)。
  • 两组术后第一年后LT4/脂肪质量比值升高趋于平台(pinteraction=0.009)。

局限性

  • 作者提出需在更大样本和更长随访时间中进一步研究以确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Obesity and hypothyroidism are common medical conditions that are associated with each other. Bariatric surgery (BS) is a common approach used to achieve substantial weight loss in obese patients. However, there is limited evidence regarding the need for postsurgery levothyroxine (LT4) dose adjustment in patients with hypothyroidism undergoing BS. Methods: This was a three-year prospective cohort study assessing postsurgery LT4 requirements with attention to body composition changes. The current study included 1030 patients with hypothyroidism, who underwent sleeve gastrectomy (SG) (n = 707, 88.3% women) or one anastomosis gastric bypass (OAGB) (n = 323, 92% women). Patients were followed for 36 months after surgery. A bioelectrical impedance analyzer was used for body composition assessment. LT4 requirements were assessed by generalized estimating equation (GEE) methods adjusted for weight as a time-varying covariate. Results: During the follow-up, TSH (mIU/L) and T4 (ng/dL) measurements did not significantly change in the OAGB group over time. However, in the SG group, TSH measurement decreased over time (ptrend = <0.001). In the third year of the follow-up, 56.1% and 33.3% of patients in the SG and OAGB groups experienced LT4 (μg/day) dose reduction, while 24.4% and 9.1% of the participants experienced LT4 dose increments, respectively. GEE analysis showed a significant increase in the LT4/fat mass (FM) (μg/kg) ratio after 36 months of follow-up compared with the baseline in both the SG [1.8 (1.5-2.2) to 2.7 (2.0-3.5), ptrend = 0.039)] and OAGB [1.7 (1.4-2.2) to 3.2 (2.7-4.8), ptrend = <0.001)] groups. Moreover, patients who underwent OAGB experienced greater LT4/FM (μg/kg) dose adjustments compared to those undergoing SG (pbetween = 0.060). In both groups, after the first year, the increase in LT4/FM (μg/kg) plateaued (pinteraction = 0.009). Conclusion: Most hypothyroid patients experienced either a reduction or no change in LT4 (μg/day) dosage after 36 months in both surgical groups. The LT4/FM (μg/kg) was significantly increased in patients undergoing either SG or OAGB with greater alterations in the latter. Further studies on larger populations and with longer duration of follow-up are needed to confirm our results.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Barzin M, Molavizadeh D, Mahdavi M, et al. Thyroid Hormone Replacement Dosing after Bariatric Surgery in Patients with Primary Hypothyroidism And Severe Obesity: Tehran Obesity Treatment Study. Thyroid. 2024. PMID: 39155815. doi:10.1089/thy.2024.0073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。